Proteomic Analysis of the Non-genetic Response to Cisplatin in Lung Cancer Cells

Overview

Journal Cancer Diagn Progn

Specialty Oncology

Date 2022 Apr 11

PMID 35399307

Authors

Cristine De Souza Dutra

Carolina Lumertz Martello

Nathan Araujo Cadore

Henrique Bunselmeyer Ferreira

Arnaldo Zaha

Karina Mariante Monteiro

Affiliations

Soon will be listed here.

Abstract

Background: Drug resistance is the main cause of therapy failure in advanced lung cancer. Although non-genetic mechanisms play important roles in tumor chemoresistance, drug-induced epigenetic reprogramming is still poorly understood.

Materials And Methods: The A549 cell line was used to generate cells with non-genetic resistance to cisplatin (CDDP), namely A549/CDDP cells. Bioorthogonal non-canonical amino acid tagging (BONCAT) and mass spectrometry were used to identify proteins modulated by CDDP in A549 and A549/CDDP cells.

Results: Proteins related to proteostasis, telomere maintenance, cell adhesion, cytoskeletal remodeling, and cell redox homeostasis were found enriched in both cell lines upon CDDP exposure. On the other hand, proteins involved in drug response, metabolic pathways and mRNA processing and splicing were up-regulated by CDDP only in A549/CDDP cells.

Conclusion: Our study revealed proteome dynamics involved in the non-genetic response to CDDP, pointing out potential targets to monitor and overcome epigenetic resistance in lung cancer.

Citing Articles

Engineered Proteins and Materials Utilizing Residue-Specific Noncanonical Amino Acid Incorporation.

Majekodunmi T, Britton D, Montclare J Chem Rev. 2024; 124(15):9113-9135.

PMID: 39008623 PMC: 11327963. DOI: 10.1021/acs.chemrev.3c00855.

References

Ma L, Zong X . Metabolic Symbiosis in Chemoresistance: Refocusing the Role of Aerobic Glycolysis. Front Oncol. 2020; 10:5. PMC: 6992567. DOI: 10.3389/fonc.2020.00005. View

Sciarrillo R, Wojtuszkiewicz A, Assaraf Y, Jansen G, Kaspers G, Giovannetti E . The role of alternative splicing in cancer: From oncogenesis to drug resistance. Drug Resist Updat. 2020; 53:100728. DOI: 10.1016/j.drup.2020.100728. View

Ishibashi T, Lippard S . Telomere loss in cells treated with cisplatin. Proc Natl Acad Sci U S A. 1998; 95(8):4219-23. PMC: 22469. DOI: 10.1073/pnas.95.8.4219. View

Marine J, Dawson S, Dawson M . Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer. 2020; 20(12):743-756. DOI: 10.1038/s41568-020-00302-4. View

Terlizzi M, Colarusso C, Pinto A, Sorrentino R . Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness. Pharmacol Ther. 2019; 202:140-148. DOI: 10.1016/j.pharmthera.2019.06.005. View

Silva J, Denny R, Dorschel C, Gorenstein M, Kass I, Li G . Quantitative proteomic analysis by accurate mass retention time pairs. Anal Chem. 2005; 77(7):2187-200. DOI: 10.1021/ac048455k. View

Amaral M, Jullyanne de Sousa Portilho A, da Silva E, DE Oliveira Sales L, Maues J, de Moraes M . Establishment of Drug-resistant Cell Lines as a Model in Experimental Oncology: A Review. Anticancer Res. 2019; 39(12):6443-6455. DOI: 10.21873/anticanres.13858. View

Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu D . The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 2018; 47(D1):D442-D450. PMC: 6323896. DOI: 10.1093/nar/gky1106. View

Damiano J, Cress A, Hazlehurst L, Shtil A, Dalton W . Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999; 93(5):1658-67. PMC: 5550098. View

10.

Hisano T, Ono M, Nakayama M, Naito S, Kuwano M, Wada M . Increased expression of T-plastin gene in cisplatin-resistant human cancer cells: identification by mRNA differential display. FEBS Lett. 1996; 397(1):101-7. DOI: 10.1016/s0014-5793(96)01150-7. View

11.

Vichai V, Kirtikara K . Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2007; 1(3):1112-6. DOI: 10.1038/nprot.2006.179. View

12.

Shaffer S, Dunagin M, Torborg S, Torre E, Emert B, Krepler C . Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. 2017; 546(7658):431-435. PMC: 5542814. DOI: 10.1038/nature22794. View

13.

Deville S, Cordes N . The Extracellular, Cellular, and Nuclear Stiffness, a Trinity in the Cancer Resistome-A Review. Front Oncol. 2019; 9:1376. PMC: 6908495. DOI: 10.3389/fonc.2019.01376. View

14.

Hu J, Sun F, Chen W, Zhang J, Zhang T, Qi M . BTF3 sustains cancer stem-like phenotype of prostate cancer via stabilization of BMI1. J Exp Clin Cancer Res. 2019; 38(1):227. PMC: 6540453. DOI: 10.1186/s13046-019-1222-z. View

15.

Shishkin S, Kovalev L, Pashintseva N, Kovaleva M, Lisitskaya K . Heterogeneous Nuclear Ribonucleoproteins Involved in the Functioning of Telomeres in Malignant Cells. Int J Mol Sci. 2019; 20(3). PMC: 6387250. DOI: 10.3390/ijms20030745. View

16.

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B . The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017; 7(3):339-348. PMC: 5651054. DOI: 10.15171/apb.2017.041. View

17.

Sharma S, Santiskulvong C, Bentolila L, Rao J, Dorigo O, Gimzewski J . Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells. Nanomedicine. 2011; 8(5):757-66. DOI: 10.1016/j.nano.2011.09.015. View

18.

Eichelbaum K, Winter M, Diaz M, Herzig S, Krijgsveld J . Selective enrichment of newly synthesized proteins for quantitative secretome analysis. Nat Biotechnol. 2012; 30(10):984-90. DOI: 10.1038/nbt.2356. View

19.

Cort A, Ozben T, Saso L, De Luca C, Korkina L . Redox Control of Multidrug Resistance and Its Possible Modulation by Antioxidants. Oxid Med Cell Longev. 2016; 2016:4251912. PMC: 4736404. DOI: 10.1155/2016/4251912. View

20.

Gillet J, Calcagno A, Varma S, Marino M, Green L, Vora M . Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A. 2011; 108(46):18708-13. PMC: 3219108. DOI: 10.1073/pnas.1111840108. View